Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

NCT ID: NCT06255197

Last Updated: 2024-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-04

Study Completion Date

2031-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lung cancer is the leading cause of cancer-related deaths in China. The recent decade witnessed rapid evolving of demographics, pathological features and prognoses of patients with surgically resected lung cancers. The introduction of minimally invasive surgery (MIS) concept and techniques, targeted therapy and immunotherapy changed treatment landscape for patients with surgically resected lung cancers. With more early-stage lung cancers discovered due to the application of CT screening, questions focusing on extent of lung resection, lymph node dissection, application of targeted or immune-therapy to early-stage lung cancers are emerging. This study aims to create a cohort of patients with surgically resected lung cancers and an analytic framework to address the aforementioned clinical questions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma Non Small Cell Lung Cancer Small-cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with surgically resected lung cancer

Patients who were diagnosed with lung cancer and received surgical resection in participating medical centers during the designed study period.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age above 18.
* Have received surgical resection for lung malignancies.

Exclusion Criteria

* Participants whose data are of low quality, poor completeness or poor internal linkage.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jie He, MD-PhD

Role: PRINCIPAL_INVESTIGATOR

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS and PUMC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fengwei Tan, MD-PhD

Role: CONTACT

+8601087787792

Renda Li, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fengwei Tan, MD

Role: primary

010-87787790

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LungReal_01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Perioperative Treatment Outcomes of Early NSCLC
NCT06610240 ENROLLING_BY_INVITATION
Survival Outcomes of Lung Cancer
NCT03647098 RECRUITING